Australians love a dark horse and Australian public company, NeuroScientific Biopharmaceuticals Ltd (NSB), is just that, leading the way against other much larger pharmaceuticals in finding a cure for Alzheimer’s disease.
As featured in ‘Nature’, ‘The Economist’ and the February 2019 issue of ‘Fortune’, Alzheimer’s research has pivoted towards a ‘radical new approach’ focused on the ‘survival’ of brain cells to combat degenerative neurological disease.
To NSB Chairman, Brian Leedman’s knowledge, NSB are the only company in the world poised to commence human studies in this specific field of research.
Leedman said, “NSB’s novel approach to cell survival was considered ‘radical’ at the time of its public listing mid-last year, but now is likely to be considered mainstream by the scientific community.
We’re moving into human trials this year, which is effectively light years ahead of the competition.”
According to Australian Institute of Health and Welfare, in 2015 there were an estimated 342,800 people living with dementia in Australia. Alzheimer’s disease is the most common type of dementia, an overall term for conditions that occur when the brain no longer functions properly.
An Access Economics report commissioned by Alzheimer’s Australia (AA) and published in March 2005, also projected that by 2050 – if no cure is found – the total number of Australians with dementia will be over 730,000, or 2.8% of the population. The costs are more than human too, with AA estimating dementia cost $8.8 billion in direct expenditure in 2016, and forecast it to rise to $16.7 billion by 2036.
NSB’s current main focus is the development of its leading drug candidate, EmtinB, towards clinical human trials, estimated to commence in Q3 of this calendar year. They are also looking to make their mark in the investment community to further their exciting research into effectively treating Alzheimer’s worldwide.
